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Background: To evaluate safety and efﬁcacy of inhaled mannitol treatment in subgroups of a large global CF population.
Methods: Data were pooled from two multicentre, double-blind, randomised, controlled, parallel group phase III studies in which 600 patients
inhaled either mannitol (400 mg) or control (mannitol 50 mg) twice a day for 26 weeks.
Results: Both the mean absolute change in FEV1 (mL) and relative change in FEV1 by % predicted from baseline for mannitol (400 mg) versus
control were statistically signiﬁcant (73.42 mL, 3.56%, both pb0.001). Increases in FEV1 were observed irrespective of rhDNase use. Signiﬁcant
improvements in FEV1 occurred in adults but not children (6–11) or adolescents (aged 12–17). Pulmonary exacerbation incidence was reduced by
29% (p=0.039) in the mannitol (400 mg) group.Abbreviations: AE, adverse event; ASL, airway surface liquid; BID, twice a day; BMI, body mass index; CF, cystic fibrosis; CFTR, CF transmembrane
conductance regulator; CI, confidence interval; DPI, dry powder inhaler; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; GRAS, generally
recognised as safe; HS, hypertonic saline; ITT, intent to treat; MCC, mucociliary clearance; MedDRA, medical dictionary for regulatory activities; MMRM,
Mixed-effects model for repeated measures; MTT, mannitol tolerance test; PA, Pseudomonas aeruginosa; PDPE, protocol defined pulmonary exacerbation; PE,
pulmonary exacerbation; SAE, serious adverse event; SD, standard deviation
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Morbidity and mortality of cystic fibrosis (CF) are mostly
related to deterioration of lung function. Many processes con-
tribute, including chronic bacterial infection, excessive inflam-
mation, production of abnormally viscid phlegm, and defective
clearance of airway secretions. All of these factors lead to airway
remodelling and progressive parenchymal disease [1].
In addition, there are episodes of acute worsening of signs and
symptoms, often called pulmonary exacerbations (PE), which are
clinically important events that have recently been shown to be
associated with accelerated and irreversible loss of lung function
[2].
Most CF treatments work downstream in the pathophysiolog-
ical process and not on the fundamental abnormalities. The under-
lying defect in the airways stems from malfunction of the CF
transmembrane conductance regulator (CFTR), which controls the
homeostasis of airway surface liquid (ASL), which is shallow in
CF. Adequate ASL depth is critical for normal airway defences, as
is optimal ciliary movement and maintenance of mucus hydration,
both of which are necessary for normal MCC. Restoration of ASL
depth is a strategy to address an underlying defect in CF and can be
achieved either by restoring CFTR function or by directly increas-
ing ASL with airway luminal application of osmotic agents.
Mannitol is a naturally occurring polyol (sugar alcohol) and is a
generally recognised as safe (GRAS) excipient for food substances
at intakes of up to 20 g/day. It is also approved for oral, intravenous
and ocular products [3]. When examined in a number of acute
[4–9], short [10–12], and long-term studies [13–15], inhaled dry
powder mannitol improved airway surface hydration and increased
MCC and cough clearance in patients with asthma, bronchiectasis
and CF [4–17]. Use in those conditions also contributed to
improved lung function [10,11] and a reduction in PEs. Based on
its mechanism of action as an osmotic agent, mannitol should be
complementary to existing therapies.
Two phase III randomised double-blind controlled studies,
referred to as CF301 and CF302 in this article, with nearly iden-
tical protocols have been conducted with inhaled mannitol in CF
patients with mild to severe pulmonary impairment [14,15]. We
present the integrated data from these studies and evaluate the
safety and efficacy of inhaled mannitol in a large population of CF
patients in order to optimise subgroup analyses by age group and
PE outcome measures.2. Methods
Data have been integrated from two six-month phase III studies
examining the safety and efficacy of inhaled mannitol in patientswith CF. The primary focus of the studies is on FEV1 because its
decline correlates with survival in CF [18–20].2.1. Study design, setting
Detailed methodologies of the individual studies have been
published elsewhere [14,15]. The study protocols and consent
were approved by the institutional review board or research
ethics committee at each participating centre, and informed written
consent was obtained. Both studies were performed in accordance
with good clinical practices and the principles expressed in the
Declaration of Helsinki.
These were multicentre, randomised, double-blind, controlled,
parallel group phase III clinical trials of very similar design. The
minimum FEV1 inclusion threshold was higher in CF302 (≥40%
predicted versus ≥30% in CF301), and quantitative sputum
microbiology and historic PE over the preceding 12 months was
gathered only in CF302.
Prior to randomisation, a mannitol initiation dose was admin-
istered to exclude patients with airway hyperresponsiveness, as
previously described [14,15]. Eligible patients were randomised
3:2 to receive 26 weeks of 400 mg inhaled mannitol or control
(mannitol 50 mg) twice a day. The randomisation schema included
rhDNase users and non-users.
Data captured at baseline and all 3 subsequent visits toWeek 26
included lung function tests, concomitant medication use, PEs,
adverse events (AEs), physical examination, and blood and sputum
microbiology assessments. Sputum weight from samples obtained
within 30 min of study drug administration, was assessed in both
studies after the administration of the first dose at visit 1 and
repeated at visit 3 (Week 14).
Subjects were pre-medicated with 400 μg of salbutamol 5–
15 min before each study drug dosing. Mannitol (Bronchitol™,
Pharmaxis Ltd., Frenchs Forest NSW, Australia) was supplied in
blister-packed 40 mg capsules (control, 5 mg capsules), together
with an inhaler device (RS01, Monodose Inhaler Model 7,
Plastiape, Milan, Italy).2.2. Study population
Eligible patients had a diagnosis of CF, were aged≥6 years,
and had a baseline FEV1 ≥30% (≥40% for CF302) and b90%
predicted. They were permitted to continue all CF therapies
including rhDNase and inhaled antibiotics but not hypertonic
saline (HS). Patients were categorised by age and rhDNase use
at screening as follows: children (6 to 11 years), adolescents
(12 to 17 years), and adults (N18 years); and rhDNase users
and non-users.
369D. Bilton et al. / Journal of Cystic Fibrosis 12 (2013) 367–3762.3. Outcome measures
The primary efficacy endpoint in both trials was the change
from baseline in FEV1. This was assessed over the 26-week
treatment-period in terms of relative percentage change of
percent predicted and absolute change (mL). Secondary
endpoints included: change from baseline in forced vital
capacity (FVC); Protocol Defined Pulmonary Exacerbations
(PDPEs) and associated antibiotic use; days in hospital and
sputum weight. The PDPEs were defined using the Fuchs
criteria [21].
Endpoints were also evaluated by subgroups based on rhDNase
use, age and presence ofPseudomonas infection. The safety profile
of inhaled mannitol included recording AEs and monitoring
changes in haematology, biochemistry and sputum microbiology
(for CF302).
Each studywas powered to determinewhether inhaledmannitol
compared with control improves FEV1 [14,15]. Pooling allowed
examination of FEV1 within sub-populations, such as by age-
group and rhDNase use. This approach also enabled analysis of
rarer but clinically important events such as PEs. Compliance was
determined by review of returned medication and empty blister
packaging.2.4. Data integration
To enable pooling and direct comparison of the two studies,
a common approach was employed, using the data derivation
conventions and analysis models defined in the Statistical
Analysis Plan for CF302. As the studies used two different
versions (Versions 9.1 and 11) of the Medical Dictionary for
Regulatory Activities (MedDRA), steps were taken to ensure
the quality of the combined AE data. Differences in collection
of historical exacerbation rates between the two studies
prevented useful assessment of a pooled rate and time to first
event but still allowed an assessment of the incidence of pooled
PEs.2.5. Statistical methods
For analyses relating to spirometry, mixed-effects models
for repeated measures (MMRM) were used, with relative
percentage change in percent predicted FEV1 and absolute
change in FEV1 (mL) from baseline in spirometry value as the
outcome variables. Fixed effect terms for treatment included
the following: rhDNase use; region (CF301) or country
(CF302) nested within the protocol; protocol time point; disease
severity as characterised by FEV1% predicted at screening; age;
gender; and baseline spirometry value. Treatment-by-time,
treatment-by-rhDNase use and treatment-by-age-group were
also included in models to estimate changes by time, by
rhDNase use and by age-group. Heterogeneity of treatment–
effect across age and rhDNase subgroups was also assessed by
the interaction terms of treatment-by-age and treatment-by-
rhDNase.3. Results
3.1. Patients
The two studies occurred between April 2007 and April
2010, with sites in Argentina, Australia, Belgium, Canada,
France, Germany, Ireland, the Netherlands, New Zealand, UK
and USA. In total, 729 patients were screened, 87 were
excluded before randomisation (of whom 41 failed the mannitol
initiation test dose (5.6%) and 27 (3.7%) did not complete it).
Following randomisation a further 42 patients were excluded
before receiving the allocated treatment (Fig. 1).
Six hundred patients received at least one dose of study
drug. The pooled population represents the expected distribu-
tion of age, disease severity and concomitant medication use
(Table 1). Patients were well distributed with respect to age,
and reasonably balanced with respect to gender, and BMI.
Average compliance (±SD) was mannitol 80.3±29.7%, control
83.3±25.3%.
3.2. Efficacy outcomes
3.2.1. Absolute (mL) and relative changes (%) in percent
predicted FEV1
Improvements in FEV1 over 26-weeks were evident in the
mannitol group versus control, by change in FEV1 by volume
(mL), and relative change (%) in percent predicted of normal,
73.42 mL (95% CI 36.19, 110.65) and 3.56% (95% CI 1.44,
5.68), respectively, both pb0.001. Mannitol improved lung
function by the first evaluation at 6-weeks and these benefits
were sustained over 26-weeks (Fig. 2).
Although improvements in FEV1 compared to control in
relative change (%) in FEV1 % predicted were not statistically
significant in children and adolescents (Fig. 3), improvements
were evident over baseline in all age groups in the mannitol arm.
When examining absolute change from baseline in FEV1 %
predicted, a significant change favouring mannitol over control
was observed in adults (2.55%, p=0.002) and children (3.14%,
p=0.03), but not in adolescents (0.60%, p=0.615). Significant
improvements in FEV1 (mL) and relative change in FEV1 %
predicted were demonstrated in rhDNase users and non-users
(Fig. 4a). The pooled effect size was 62.65 mL (95% CI 16.22,
109.07; p=0.008) or 3.01% (95% CI 0.36, 5.66; p=0.026)
among rhDNase users, and 92.88 mL (95% CI 28.61, 157.14;
p=0.005) or 4.52% (95% CI 0.87, 8.17; p=0.015) in non-users.
The effect size of mannitol in rhDNase users versus non-rhDNase
users was not significantly different.
In the Pseudomonas positive sub-group the difference in mean
change in FEV1 (mL) from baseline for mannitol (125.98 mL) vs
control (15.76 mL) was statistically significant, 110.22 mL,
(95% CI 57.71, 162.72; pb0.001) over 26 week treatment,
which compares favourably to findings in the overall study
population (73.42 mL).
3.2.2. Other spirometry measures: FVC
Analysis of changes in FVC provides support for the beneficial
effect of mannitol in CF patients. The treatment-effect on FVC,
Assessed for eligibility (n=729)
Randomised (n=642)
Excluded (n=87)
• Positive MTT 41 (5.6%)
• Failed to complete MTT‡ 27 (3.7%)
• Other# 19 (2.6%)
Allocated to mannitol (n=384)
• Received allocated intervention (n=361)
• Did not receive intervention (n=23)
oAdverse event 4 (1.0%)
oConsent withdrawn 9 (2.3%)
oSponsor decision 4 (1.0%)
oPhysician decision 1 (0.3%)
oIneligible† 4 (1.0%)
oLost to follow-up 1 (0.3%)
Allocated to control (n=258) 
• Received allocated intervention (n=239)
• Did not receive intervention (n=19)
oAdverse event 3 (1.2%)
oConsent withdrawn 8 (3.1%)
oSponsor decision 3 (1.2%)
oPhysician decision 1 (0.4%)
oIneligible† 1 (0.4%)
oProtocol violation 3 (1.2%)
96 discontinued mannitol 
• Adverse event 42 (11.6%)
• Patient decision 41 (11.4%)
• Sponsor decision 1 (0.3%)
• Physician decision 8 (2.2%)
• Protocol violation 1 (0.3%)
• Other 2 (0.6%)
• Lost to follow-up 1 (0.3%)
46 discontinued control 
• Adverse event 15 (6.3%)
• Patient withdrew consent  29 (12.1%)
• Physician decision 1 (0.4%)
• Other 1 (0.4%)
• Protocol violation 1 (0.4%)
• Lost to follow-up 1 (0.4%)
Analysed:
•ITT/Safety (n=361)
•Included in MMRM analysis (n=334)*
Analysed:
•ITT/Safety (n=239)
•Included in MMRM analysis (n=232)* 
‡ Subjects unable to complete the MTT and therefore assessed as ineligible for continued treatment
# Additional patients excluded for non-attendance to V1 (within 5 week time limit) or due to exacerbation
† Randomised in error
* Patients with at least one post-baseline data were included in the MMRM analysis
Fig. 1. Flow-chart of the study.
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1.27, 4.74; pb0.001) generally mirrored the treatment-effect on
FEV1 (Fig. 4a and b); it generally favoured mannitol in all
age-groups, but was largest in children, and was significant in
children and adults, 6.13% (95% CI 2.07, 10.19; p=0.003), and
3.01% (95% CI 0.67, 5.35; p=0.012) respectively. FVC
significantly improved in both rhDNase users, 87.44 mL (95%
CI 31.55, 143.33; p=0.002) or 2.27% (95% CI 0.10, 4.44; p=
0.041) and non-users, 119.11 mL (95% CI 41.72, 196.51; p=
0.003) or 4.34% (95% CI 1.35, 7.33; p=0.004).
3.2.3. Exacerbation associated events
The incidence of patients with protocol defined pulmonary
exacerbations (PDPEs) was lower in the mannitol group (17%)than in the control group (23%) during the studies. Incidences
of exacerbation and associated rescue antibiotic use were reduced
by 29% (95% CI 0.51, 0.98; p=0.039) (Fig. 5a) and 30% (95%
CI 0.50, 0.97; p=0.033), respectively. Although the studies
were not adequately powered to draw firm conclusions about
the rate of pulmonary exacerbations within subgroups, the
relative risk of PDPEs by age and rhDNase use are shown in
Fig. 5a. The 22% reduction in PDPE-related hospitalisation
incidence did not reach statistical significance (p=0.219). The
time to first exacerbation (Fig. 5b) correlated with the time to
first exacerbation-related hospitalisation and first antibiotic use.
The hazard ratio for time to first exacerbation for mannitol
compared with control was 0.68 (95%CI 0.42, 1.11; p=0.119) in
Study CF301 and 0.74 (95% CI 0.42, 1.32; p=0.308) in CF302.
Table 1








Male 200 (55.4) 120 (50.2)
Female 161 (44.6) 119 (49.8)
Age, years
Mean (SD); range 21.3 (10.7); 6–56 21.6 (10.5); 6–53
Age groups n (%)
≤11 yrs 66 (18.3) 41 (17.2)
12–17 yrs 88 (24.4) 64 (26.8)
≥18 yrs 207 (57.3) 134 (56.1)
FEV1 (% predicted)
Mean (SD); range 63.6 (16.1); 25–105 61.9 (16.0); 30–100
≤11 yrs 74.9 (14.1); 44–105 68.7 (13.0); 44–100
12–17 yrs 64.2 (14.9); 25–88 64.8 (16.6); 31–95
≥18 yrs 59.8 (15.6); 26–93 58.4 (15.8); 30–92
FEV1 (L)
Mean (SD) 2.06 (0.79) 1.95 (0.71)
Range 0.61–4.92 0.75–4.12
BMI (kg/m2)
Mean (SD); range 20.6 (4.08); 12.8–44.6 20.1 (3.65); 11.7–33.4
Race n (%)
Caucasian 351 (97.2) 234 (97.9)
African descent 2 (0.6) 2 (0.8)
East/South-east Asian 0 (0.0) 1 (0.4)
West Asian 3 (0.8) 1 (0.4)
Indigenous 1 (0.3) 0 (0.0)
Other 4 (1.1) 1 (0.4)
rhDNase treatment n (%) 233 (64.5) 159 (66.5)
Pseudomonas positive n (%) 164 (45.4) 119 (49.8)
Definitions of abbreviations: BID = twice a day; BMI = body mass index; SD =
standard deviation.
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Mean and median sputum weights collected in standardised
fashion as per protocol for 30 min post dosing for the overall
ITT population were higher in the mannitol group than in the









































Fig. 2. Mean absolute (mL) change fromboth time zero, mannitol median 3.0 g versus control 1.1 g
(pb0.0001), and at week 14, mannitol median 2.0 g versus
control 1.0 g, (p=0.0060). Positive trends in subgroups were
consistent with overall findings.
3.3. Safety
A total of 361 patients received mannitol, and 239 received
control during the 26-week double-blind treatment phase. A
similar incidence of AEs was seen between treatment-arms in
sub-groups of age and rhDNase use. Condition aggravated,
headache and cough were the most commonAEs. Fewer children
experienced serious AEs, and more adults discontinued the study
due to an AE.
Adverse events led to patient withdrawal in 11.6% of the
mannitol group and 6.3% of the control group. Most events were
assessed as not-related to treatment (Table 2) and were consistent
with the underlying disease state. The most commonly reported
event was condition aggravated (representing exacerbation),
which occurred less frequently in the mannitol group (36.8%)
than control (40.2%). One death occurred 3 months after study
discontinuation and was considered unrelated to study treatment.
Serious AEs considered treatment-related were infrequent
(Table 2).
As mannitol 800 mg daily represents only a fraction of that
found in a normal diet, safety analysis focused on respiratory
events. Cough was the most frequently reported respiratory event
(mannitol 21.1% versus control 16.7%). No respiratory events
were serious; however, cough was the most frequent event
leading to discontinuation (Table 2). Haemoptysis incidence was
13.3% versus 13.4% for the mannitol and control arms,
respectively. Massive haemoptysis was also similar between
respective treatment groups (0.55% versus 0.42%) which was
similar to the background rate (1.1%) reported in the CFF
Registry [22]. Bronchospasmwas a rare event, reported as serious
in one adult in the mannitol group who had a 21% post-dose
FEV1 fall upon first administration (16% fall from baseline). He4 16 18 20 22 24 26
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p=0.130 Δ = 1.12%
p=0.597
n=66 n=41 n=88   n=64                              n=207   n=134 
Fig. 3. % Change from baseline in % FEV1 predicted by age— ITT population.
Fig. 4. a. Forest plot of FEV1 % change of % predicted. b. Forest plot of FVC % change of % predicted.
372 D. Bilton et al. / Journal of Cystic Fibrosis 12 (2013) 367–376
Fig. 5. a. Relative risk for protocol defined pulmonary exacerbation by subgroups— ITT population. b. Time to first protocol defined pulmonary exacerbation— ITT
population.
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per protocol.
Dyspnoea, wheezing and chest discomfort were infrequent.
Similar proportions of patients in the mannitol and control groups
(6.1% and 5.0%, respectively) experienced one or more of these
events.
There were no meaningful between-treatment differences in
the recovery rate of Pseudomonas aeruginosa, Staphylococcus
aureus and Burkholderia cepacia sp. from sputum; haematology
and biochemistry values; or physical examination findings.4. Discussion
Most morbidity and mortality in CF is due to respiratory
disease, caused by tenacious dehydrated sputum, which serves
as a nidus for infection and inflammation. Inhaled mannitol,
working as an osmotic agent, can restore periciliary fluid and
improve mucociliary clearance. We have previously seen that
mannitol can replenish ASL and thereby improve mucus
clearance. Study findings demonstrate that inhaled mannitol is
a safe and convenient treatment [10]. The therapeutic benefit is
Table 2









Patients with ≥1 AE 88.4 90.0
Patients with ≥1 AE leading to discontinuation
from the study
11.4 6.3
AEs by MedDRA preferred term (occurring in ≥10%
patients overall) a:
Condition aggravated 36.8 40.2
Cough 21.1 16.7
Headache 17.7 20.9
Haemoptysis b 13.3 13.4
Pharyngolaryngeal pain 12.2 7.5
Bacteria sputum identified 10.8 11.3
Nasopharyngitis 10.2 9.6
Lower respiratory tract infection 6.1 10.0
Patients with ≥1 SAE 21.3 27.2
SAEs by MedDRA preferred term (occurring in ≥1%
patients overall) a:
Condition aggravated 16.6 18.8
Lower respiratory tract infection 1.1 2.1
Haemoptysis 2.2 0.8
Definitions of abbreviations: AE = adverse event; SAE = serious adverse event;
MedDRA = Medical Dictionary for Regulatory Activities.
a Patients are counted once for each unique preferred term identiﬁed from the
CRF verbatim text.
b Includes haemoptysis captured as a component of a PE/PDPE but not
necessarily reported as an AE and also events reported as AEs. For haemoptysis
reported only as an AE, the incidence between the groups was 9.4% vs. 5.4%
for the bronchitol and control arms respectively.
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mild to severe disease regardless of concomitant treatment with
rhDNase [14,15].
Importantly, in the combined database from two clinical trials
(CF301 and CF302) we also observed reduced frequency of
PDPEs in patients treated with inhaled mannitol. Exacerbations
lead to an irreversible loss of lung function and also pose a
significant immediate treatment burden, associated with impaired
quality of life [2,23]. Thus, sustained improvement in FEV1
combined with less frequent exacerbations should result in a
reduced rate of decline in lung function, and potentially improved
quality and length of life.
Absolute change in FEV1 % predicted was significantly
improved by mannitol over control in both adults and younger
children (6–11 years). Improvements in FEV1 over baseline were
evident in all age-groups in themannitol 400 mg arm, with patients
aged 6–11 years showing the largest changes from baseline. The
relative effect compared with control (50 mg mannitol) was not
significant in children and adolescents but was in adults. The
variability in treatment-effect between the age-groups is consistent
with expected natural sampling variation and was most apparent in
the control arms. Statistical testing for age effects and heteroge-
neity of results showed that the results are consistent with a
homogeneous treatment-effect. Despite numerical differences,
neither the interaction between treatment and age-group, nor the
heterogeneity test was significant, and confidence intervals overlap(Fig. 4a). Natural sample variation on subgroup analyses is the
most likely explanation for the observed differences.
Apparent treatment differences by age in CF are not unique to
mannitol. In an inhaled tobramycin study there were large
differences in the placebo arm of children compared to adoles-
cents [24]. We acknowledge that other explanations may also be
possible. For example, CF management in adolescents can be
particularly challenging and adherence to pre-existing therapy
might have changed as a result of study participation. In addition,
the methodology of using returned medication and empty blister
packages has recognised limitations as a measure of true ad-
herence. Secondly, although a dose-finding study suggested that
the 50 mg control dose was sub-therapeutic in all ages [25], some
effect cannot be excluded, in which case the effect size would be an
underestimation of the true benefit of mannitol therapy. Neverthe-
less, effect size differences by age remain consistent with normal
sampling variation expected with subgroup analysis.
Total sputum weight following study drug administration was
evaluated in both studies. Greater post-mannitol sputum weight
compared with control at week-0 and at week-14 indicates im-
proved MCC or increased periciliary volume brought about by the
treatment and provides an objective measure of short term
medication effect based on the drug's mechanism of action.
Mannitol for inhalation is a dry-powder that does not require
refrigeration or nebulisation. It is delivered from a simple, dis-
posable, capsule-based dry-powder inhaler. In the two trials,
inhaled mannitol was generally well tolerated, and adherence was
above 80%, suggesting that 10 capsules per dose is acceptable to
most patients.
The pattern of AEs was similar between treatment groups,
irrespective of age or rhDNase use. Cough was slightly more
frequent in the mannitol group than control group, although not
among children. The proportion of patients experiencing AEs
pertaining to bronchospasm was remarkably low and comparable
between groups with no evidence of bronchoconstriction emerging
over time. The incidence of post-dose fall in FEV1 with mannitol
administration was lower than has been reported with inhaled
antibiotics such as tobramycin powder and aztreonam. [26,27]
Although inhaled mannitol, like HS and other inhaled therapies,
can cause bronchoconstriction in sensitive individuals, employ-
ment of screening testing and pre-dosing with a bronchodilator, as
performed in these studies, appear to successfully mitigate the risk.
Although there have been no head to head studies comparing
mannitol with HS, these mannitol studies show changes in FEV1
(mLs) from baseline that compare favourably with those reported
in an earlier HS study [28]. The number of patients needed to be
treated to prevent a similarly defined exacerbation over 48 weeks
was 8 in both the pooled mannitol and HS studies. Further, the
improvements seen with mannitol were in patients already
receiving current CF treatments. It is not clear if HS impacts a
well-treated population.
An important hypothetical concern relates to whether mannitol
might act as a substrate to promote increased bacterial growth in
vivo (P. aeruginosa and S. aureus grow with mannitol in vitro)
[29]. Reassuringly, there was no significant difference between
the treatment groups for changes in the rates of detection of these
respiratory pathogens. Fewer patients in the mannitol group
375D. Bilton et al. / Journal of Cystic Fibrosis 12 (2013) 367–376required antibiotics or suffered exacerbations during the study.
Concurrent infection with B. cepacia sp. was uncommon and did
not increase over the course of therapy. Treatment with inhaled
mannitol was associated with significantly improved lung function
that was sustained over 6 months, even in those patients receiving
best standard of care for Pseudomonas infection. This finding is
clinically important, as these patients are at particularly high
risk for accelerated pulmonary decline. Interestingly, a recent
study exploring the aminoglycoside gentamicin in combination
with mannitol demonstrated that mannitol and gentamicin could
potentiate the eradication of gram negative bacterial persisters
and biofilms, suggesting that mannitol may actually improve
antibiotic effectiveness [30].
In conclusion, inhaled mannitol is a convenient and well-
tolerated new therapy for CF that has a good safety profile and
provides sustained benefit in lung function comparable with
existing treatments. Furthermore, use of inhaled mannitol was
associated with a reduction in the frequency of PEs. These
improvements were all observed in a heavily treated CF
population, indicating that the effects of inhaled mannitol are
additive to state of the art care, thus enhancing the clinical
relevance of the study findings.
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